Eczema Vaccinatum Treated with N-Methylisatin -Thiosemicarbazone

Metabolic removal of sulfur from 1-methylisatin 3-thiosemicarbazone.

The efficacy of 1-methylisatin 3-thiosemicarbazone for the inhibition of neurovaccinia virus in mice has been documented by D. J. Bauer and P. W. Sadler (Brit. J. Pharmacol. 15:101, 1960). The inhibition of adenovirus multiplication by this compound has been reported by D. J. Bauer and K. Apostolov (Science 154:796, 1966). The present communication pertains to the microbial conversion of 1-meth...

Protective murine and human monoclonal antibodies against eczema vaccinatum.

BACKGROUND Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema). METHODS Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum. ...

Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections

INTRODUCTION It has been more than 22 years since the last case of smallpox was confirmed and 20 years since the World Health Organization declared that the global eradication of smallpox had been achieved. The subsequent discontinuation of vaccination against smallpox (with vaccinia virus [VV] vaccine) has rendered most humans vulnerable to smallpox infection. The recent outbreak of monkeypox ...

Implications for Eczema Vaccinatum Selective Killing of Vaccinia Virus by LL-37:

Vaccinia immune globulin ameliorates eczema vaccinatum in a murine model of atopic dermatitis

Supplemental Figure Legends 182 Figure S1. Experimental design of VIG treatment using a murine model of EV. Mice 183 were EC sensitized with OVA or saline for 7 weeks followed by inoculation of 10 7 plaque 184 forming units/mouse by skin scarification. Mice were sacrificed after 7 days of VV inoculation 185 and examined for clinical responses, viral load, serum levels of VV antibodies and cytok...